



US008372072B2

(12) **United States Patent**  
**Lindenbaum et al.**

(10) **Patent No.:** **US 8,372,072 B2**  
(45) **Date of Patent:** **\*Feb. 12, 2013**

(54) **METHODS AND APPARATUS FOR HEMOSTASIS FOLLOWING ARTERIAL CATHETERIZATION**

(75) Inventors: **Hayim Lindenbaum**, Haifa (IL);  
**Shimon Eckhouse**, Haifa (IL)

(73) Assignee: **Cardiodex Ltd.**, Cesarea Business Park (IL)

(\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

1,731,069 A	10/1929	Herman
1,881,250 A	10/1932	Tomlinson
1,983,669 A	12/1934	Kimble
2,144,090 A	1/1939	Spencer
2,790,442 A	4/1957	Donaldson
2,808,833 A	10/1957	August
3,100,489 A	8/1963	Bagley
3,176,114 A	3/1965	Kneisley
3,301,258 A	1/1967	Werner et al.
3,302,635 A	2/1967	Pittman
3,494,364 A	2/1970	Peters
3,500,828 A	3/1970	Podhora
3,532,095 A	10/1970	Miller
3,595,238 A	7/1971	Gavrilov et al.
3,613,682 A	10/1971	Naylor
3,636,943 A	1/1972	Balamuth
3,699,967 A	10/1972	Anderson
3,794,040 A	2/1974	Balamuth

(Continued)

(21) Appl. No.: **13/302,662**

(22) Filed: **Nov. 22, 2011**

(65) **Prior Publication Data**

US 2012/0065637 A1 Mar. 15, 2012

**Related U.S. Application Data**

(63) Continuation of application No. 11/797,294, filed on May 2, 2007, now abandoned, which is a continuation of application No. 10/616,887, filed on Jul. 10, 2003, now Pat. No. 7,223,266, which is a continuation-in-part of application No. 10/358,130, filed on Feb. 4, 2003, now Pat. No. 7,115,127.

(51) **Int. Cl.**  
**A61B 18/14** (2006.01)

(52) **U.S. Cl.** ..... **606/49**; 606/213

(58) **Field of Classification Search** ..... 606/27, 606/40-41, 49-50, 192, 194, 213; 604/96.01-104  
See application file for complete search history.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

524,417 A	8/1894	Fahey
1,596,004 A	8/1926	De Bengoa

**FOREIGN PATENT DOCUMENTS**

CA	2514865 A1	8/2004
CA	2587228 A1	5/2006

(Continued)

**OTHER PUBLICATIONS**

U.S. Appl. No. 60/630,245, filed Nov. 22, 2004, Mizrahi et al.

(Continued)

*Primary Examiner* — Michael Peffley


*Assistant Examiner* — Samantha Good

(74) *Attorney, Agent, or Firm* — Venable LLP

(57) **ABSTRACT**

A method for producing hemostasis of an artery of a patient having a puncture following arterial catheterization including introducing a hemostasis device including at least one electrode into the vicinity of the puncture, supplying an electric current to the at least one electrode, thereby heating blood in the vicinity of the puncture and causing coagulation of the blood and subsequently removing the hemostasis device from the patient.

**16 Claims, 11 Drawing Sheets**



U.S. PATENT DOCUMENTS							
3,801,766	A	4/1974	Morrison, Jr.	4,790,819	A	12/1988	Li et al.
3,801,800	A	4/1974	Newton	4,801,293	A	1/1989	Jackson
3,825,004	A	7/1974	Durden, III	4,832,688	A	5/1989	Sagae et al.
3,858,586	A	1/1975	Lessen	4,834,725	A	5/1989	Iwatschenko
3,874,388	A	4/1975	King et al.	4,836,204	A	6/1989	Landymore et al.
3,886,944	A	6/1975	Jamshidi	4,848,337	A	7/1989	Shaw et al.
3,920,021	A	11/1975	Hiltebrandt	4,848,339	A	7/1989	Rink et al.
3,929,137	A	12/1975	Gonser	4,848,352	A	7/1989	Pohndorf et al.
3,938,527	A	2/1976	Rioux et al.	4,850,960	A	7/1989	Grayzel
3,963,030	A	6/1976	Newton	4,852,568	A	8/1989	Kensey
3,978,863	A	9/1976	Fettel et al.	4,854,320	A	8/1989	Dew et al.
3,980,085	A	9/1976	Ikuno	4,860,745	A	8/1989	Farin et al.
4,003,380	A	1/1977	Wien	4,869,248	A	9/1989	Narula
4,007,743	A	2/1977	Blake	4,890,612	A	1/1990	Kensey
4,011,872	A	3/1977	Komiya	4,900,303	A	2/1990	Lemelson
4,014,343	A	3/1977	Esty	4,917,089	A	4/1990	Sideris
4,016,881	A	4/1977	Rioux et al.	4,920,980	A	5/1990	Jackowski
4,043,342	A	8/1977	Morrison, Jr.	4,921,478	A	5/1990	Solano et al.
4,051,855	A	10/1977	Schneiderman	4,929,246	A *	5/1990	Sinofsky ..... 606/8
4,054,143	A	10/1977	Bauer	4,938,761	A	7/1990	Ensslin
4,074,718	A	2/1978	Morrison, Jr.	4,943,290	A	7/1990	Rexroth et al.
4,112,950	A	9/1978	Pike	4,946,463	A	8/1990	Wright
4,122,853	A	10/1978	Smith	4,953,559	A	9/1990	Salerno
4,162,673	A	7/1979	Patel	4,960,133	A	10/1990	Hewson
4,168,708	A	9/1979	Lepley, Jr. et al.	4,961,729	A	10/1990	Vaillancourt
4,198,957	A	4/1980	Cage et al.	4,979,948	A	12/1990	Geddes et al.
4,202,337	A	5/1980	Hren et al.	4,994,060	A	2/1991	Rink et al.
4,211,230	A	7/1980	Woltosz	5,002,051	A	3/1991	Dew et al.
4,215,699	A	8/1980	Patel	5,006,119	A	4/1991	Acker et al.
4,228,800	A	10/1980	Degler, Jr. et al.	5,009,656	A	4/1991	Reimels
4,230,119	A	10/1980	Blum	5,013,312	A	5/1991	Parins et al.
4,269,174	A	5/1981	Adair	5,021,059	A	6/1991	Kensey et al.
4,271,839	A	6/1981	Fogarty et al.	5,035,695	A	7/1991	Weber, Jr. et al.
4,271,847	A	6/1981	Stokes	5,038,789	A	8/1991	Frazin
4,273,127	A	6/1981	Auth et al.	5,047,025	A	9/1991	Taylor et al.
4,303,073	A	12/1981	Archibald	5,047,028	A	9/1991	Qian
4,314,555	A	2/1982	Sagae	5,049,148	A	9/1991	Mehl
4,314,559	A	2/1982	Allen	5,053,046	A	10/1991	Janese
4,317,445	A	3/1982	Robinson	5,057,105	A	10/1991	Malone et al.
4,327,709	A	5/1982	Hanson et al.	5,061,267	A	10/1991	Zeiber
4,352,924	A	10/1982	Wooten et al.	5,061,274	A	10/1991	Kensey
4,353,371	A	10/1982	Cosman	5,073,166	A	12/1991	Parks et al.
4,359,052	A	11/1982	Staub	5,078,743	A	1/1992	Mikalov et al.
4,364,392	A	12/1982	Strother et al.	5,080,660	A	1/1992	Buelna
4,370,980	A	2/1983	Lottick	5,085,659	A	2/1992	Rydell
4,390,018	A	6/1983	Zukowski	5,087,256	A	2/1992	Taylor et al.
4,404,971	A	9/1983	LeVeen et al.	5,088,997	A	2/1992	Delahuerga et al.
4,411,266	A	10/1983	Cosman	5,103,804	A	4/1992	Abele et al.
4,418,692	A	12/1983	Guay	5,108,392	A	4/1992	Spingler
4,424,833	A	1/1984	Spector et al.	5,108,420	A	4/1992	Marks
4,470,415	A	9/1984	Wozniak	5,108,421	A	4/1992	Fowler
4,476,862	A	10/1984	Pao	RE33,925	E	5/1992	Bales et al.
4,481,057	A	11/1984	Beard	5,116,332	A	5/1992	Lottick
4,483,338	A	11/1984	Bloom et al.	5,122,137	A	6/1992	Lennox
4,492,231	A	1/1985	Auth	5,122,139	A	6/1992	Sutter
4,498,475	A	2/1985	Schneiderman	5,129,882	A	7/1992	Weldon et al.
4,520,823	A	6/1985	LeVeen et al.	5,131,394	A	7/1992	Gehlbach
4,522,205	A	6/1985	Taylor et al.	5,133,714	A	7/1992	Beane
4,532,924	A	8/1985	Auth et al.	5,141,515	A	8/1992	Eberbach
4,539,987	A	9/1985	Nath et al.	5,147,316	A	9/1992	Castillenti
4,548,207	A	10/1985	Reimels	5,147,357	A	9/1992	Rose et al.
4,625,724	A	12/1986	Suzuki et al.	5,151,098	A	9/1992	Loertscher
4,637,392	A	1/1987	Sorochenko	5,151,102	A	9/1992	Kamiyama et al.
4,645,491	A	2/1987	Evans	5,156,613	A	10/1992	Sawyer
4,654,024	A	3/1987	Crittenden et al.	5,158,561	A	10/1992	Rydell et al.
4,671,274	A	6/1987	Sorochenko	5,159,925	A	11/1992	Neuwirth et al.
4,672,969	A	6/1987	Dew	5,178,620	A	1/1993	Eggers et al.
4,682,596	A	7/1987	Bales et al.	5,183,464	A	2/1993	Dubrul et al.
4,708,136	A	11/1987	Saito	5,188,602	A	2/1993	Nichols
4,709,698	A	12/1987	Johnston et al.	5,188,634	A	2/1993	Hussein et al.
4,716,897	A	1/1988	Noguchi et al.	5,190,541	A	3/1993	Abele et al.
4,717,381	A	1/1988	Papantonakos	5,192,300	A	3/1993	Fowler
4,735,201	A	4/1988	O'Reilly	5,192,302	A	3/1993	Kensey et al.
4,744,359	A	5/1988	Hatta et al.	5,207,675	A	5/1993	Canady
4,744,364	A	5/1988	Kensey	5,211,624	A	5/1993	Cinberg et al.
4,760,847	A	8/1988	Vaillancourt	5,215,103	A	6/1993	Desai
4,765,331	A	8/1988	Petruzzi et al.	5,217,024	A	6/1993	Dorsey et al.
4,776,349	A	10/1988	Nashef et al.	5,217,451	A	6/1993	Freitas
				5,217,458	A	6/1993	Parins

# US 8,372,072 B2

5,217,459 A	6/1993	Kamerling	5,951,589 A	9/1999	Epstein et al.
5,217,460 A	6/1993	Knoepfler	5,964,782 A	10/1999	Lafontaine et al.
5,220,924 A	6/1993	Frazin	5,984,950 A	11/1999	Cragg et al.
5,221,259 A	6/1993	Weldon et al.	6,002,361 A	12/1999	Schipper
5,221,281 A	6/1993	Klicek	6,007,563 A	12/1999	Nash et al.
5,222,974 A	6/1993	Kensley et al.	6,022,336 A	2/2000	Zadno-Azizi et al.
5,226,908 A	7/1993	Yoon	6,022,361 A	2/2000	Epstein et al.
5,230,349 A	7/1993	Langberg	6,033,398 A	3/2000	Farley et al.
5,257,635 A	11/1993	Langberg	6,033,401 A	3/2000	Edwards et al.
5,258,000 A	11/1993	Gianturco	6,045,569 A	4/2000	Kensley et al.
5,258,006 A	11/1993	Rydell et al.	6,048,358 A	4/2000	Barak
5,269,780 A	12/1993	Roos	6,056,768 A	5/2000	Cates et al.
5,275,616 A	1/1994	Fowler	6,056,769 A	5/2000	Epstein et al.
5,277,696 A	1/1994	Hagen	6,063,085 A *	5/2000	Tay et al. .... 606/50
5,281,216 A	1/1994	Klicek	6,071,277 A	6/2000	Farley et al.
5,282,799 A	2/1994	Rydell	6,071,300 A	6/2000	Brenneman et al.
5,282,827 A	2/1994	Kensley et al.	6,080,183 A	6/2000	Tsugita et al.
5,290,310 A	3/1994	Makower et al.	6,090,130 A	7/2000	Nash et al.
5,292,332 A	3/1994	Lee	6,104,291 A	8/2000	Beauvillier et al.
5,304,117 A	4/1994	Wilk	6,111,424 A	8/2000	Bosacchi
5,304,214 A	4/1994	DeFord et al.	6,113,598 A	9/2000	Baker
5,306,254 A	4/1994	Nash et al.	6,120,524 A	9/2000	Taheri
5,320,639 A	6/1994	Rudnick	6,126,635 A	10/2000	Simpson et al.
5,324,306 A	6/1994	Makower et al.	6,142,994 A	11/2000	Swanson et al.
5,342,359 A	8/1994	Rydell	6,152,920 A	11/2000	Thompson et al.
5,342,393 A	8/1994	Stack	6,179,832 B1	1/2001	Jones et al.
5,349,166 A	9/1994	Taylor	6,179,863 B1	1/2001	Kensley et al.
5,364,389 A	11/1994	Anderson	6,217,574 B1	4/2001	Webster
5,370,660 A	12/1994	Weinstein et al.	6,228,082 B1	5/2001	Baker et al.
5,383,896 A	1/1995	Gershony et al.	6,235,027 B1	5/2001	Herzon
5,383,899 A	1/1995	Hammerslag	6,267,758 B1	7/2001	Daw et al.
5,411,520 A	5/1995	Nash et al.	6,287,322 B1	9/2001	Zhu et al.
5,413,571 A	5/1995	Katsaros et al.	6,306,133 B1	10/2001	Tu et al.
5,415,657 A	5/1995	Taymor-Luria	6,315,787 B1	11/2001	Tsugita et al.
5,417,689 A	5/1995	Fine	6,322,559 B1	11/2001	Daulton et al.
5,419,195 A	5/1995	Quinn	6,350,274 B1	2/2002	Li
5,419,765 A	5/1995	Weldon et al.	6,352,533 B1	3/2002	Ellman et al.
5,431,639 A	7/1995	Shaw	6,368,341 B1	4/2002	Abrahamson
5,437,631 A	8/1995	Janzen	6,371,964 B1	4/2002	Vargas et al.
5,441,517 A	8/1995	Kensley et al.	6,371,974 B1	4/2002	Brenneman et al.
5,454,833 A	10/1995	Boussignac et al.	6,398,780 B1	6/2002	Farley et al.
5,458,573 A	10/1995	Summers	6,398,782 B1	6/2002	Pecor et al.
5,486,195 A	1/1996	Myers et al.	6,402,745 B1	6/2002	Wilk
5,507,744 A	4/1996	Tay et al.	6,409,739 B1	6/2002	Nobles et al.
5,540,715 A	7/1996	Katsaros et al.	6,443,947 B1	9/2002	Marko et al.
RE35,330 E	9/1996	Malone et al.	6,450,989 B2	9/2002	Dubrul et al.
5,593,406 A	1/1997	Eggers et al.	6,451,007 B1	9/2002	Koop et al.
5,611,798 A	3/1997	Eggers	6,468,272 B1	10/2002	Koblish et al.
5,624,452 A	4/1997	Yates	6,482,179 B1	11/2002	Chu et al.
5,626,601 A	5/1997	Gershony et al.	6,503,247 B2	1/2003	Swartz et al.
5,630,833 A	5/1997	Katsaros et al.	6,508,828 B1	1/2003	Akerfeldt et al.
5,645,566 A	7/1997	Brenneman et al.	6,511,479 B2	1/2003	Gentelia et al.
5,654,566 A	8/1997	Johnson	6,512,458 B1	1/2003	Kobayashi et al.
5,676,689 A	10/1997	Kensley et al.	6,529,756 B1	3/2003	Phan et al.
5,700,277 A	12/1997	Nash et al.	6,533,778 B2	3/2003	Herzon
5,702,387 A	12/1997	Arts et al.	6,537,299 B1	3/2003	Hogendijk et al.
5,716,325 A	2/1998	Bonutti	6,551,313 B1	4/2003	Levin
5,716,375 A	2/1998	Fowler	6,569,161 B2	5/2003	Zappala
RE35,755 E	3/1998	Qian	6,569,182 B1 *	5/2003	Balceta et al. .... 606/200
5,725,551 A	3/1998	Myers et al.	6,589,237 B2	7/2003	Woloszko et al.
5,728,122 A	3/1998	Leschinsky et al.	6,593,853 B1	7/2003	Barrett et al.
5,728,133 A	3/1998	Kontos	6,626,899 B2	9/2003	Houser et al.
5,728,134 A *	3/1998	Barak ..... 606/214	6,626,901 B1	9/2003	Treat et al.
5,746,755 A	5/1998	Wood et al.	6,656,136 B1	12/2003	Weng et al.
5,782,860 A	7/1998	Epstein et al.	6,656,207 B2	12/2003	Epstein et al.
5,782,861 A	7/1998	Cragg et al.	6,657,447 B1	12/2003	Parandoosh
5,810,810 A	9/1998	Tay et al.	6,669,262 B1	12/2003	Crotty, III et al.
5,836,945 A	11/1998	Perkins	6,676,657 B2	1/2004	Wood
5,853,421 A	12/1998	Leschinsky et al.	6,676,685 B2	1/2004	Pedros et al.
5,868,778 A	2/1999	Gershony et al.	6,679,904 B2	1/2004	Gleeson et al.
5,879,499 A	3/1999	Corvi	6,682,526 B1	1/2004	Jones et al.
5,891,138 A	4/1999	Tu et al.	6,689,126 B1	2/2004	Farley et al.
5,895,386 A	4/1999	Odell et al.	6,712,804 B2	3/2004	Roue et al.
5,906,636 A	5/1999	Casscells, III et al.	6,712,806 B2	3/2004	St. Germain et al.
5,911,719 A	6/1999	Eggers	6,712,815 B2	3/2004	Sampson et al.
5,922,009 A	7/1999	Epstein et al.	6,719,257 B1	4/2004	Greene et al.
5,928,266 A	7/1999	Kontos	6,743,195 B2	6/2004	Zucker
5,941,897 A	8/1999	Myers	6,768,086 B2	7/2004	Sullivan et al.
5,944,730 A	8/1999	Nobles et al.	6,772,013 B1	8/2004	Ingle et al.



WO	WO-2005/074364	A2	8/2005
WO	WO-2006/054170	A1	5/2006
WO	WO-2007/010391	A1	1/2007
WO	WO-2009/023866	A1	2/2009
WO	WO-2009/046356	A1	4/2009

## OTHER PUBLICATIONS

U.S. Appl. No. 60/935,484, filed Aug. 15, 2007, Mizrahi et al.  
 U.S. Appl. No. 60/960,604, filed Oct. 5, 2007, Mizrahi et al.  
 U.S. Appl. No. 61/006,926, filed Feb. 6, 2008, Mizrahi et al.  
 U.S. Appl. No. 09/598,232, filed Jun. 21, 2000, Zucker.  
 "About AVD", <http://www.compressar.com/about/index.shtml>; Advanced Vascular Dynamics; last accessed Jun. 22, 2009; (Copyright (2006)); (p. 1).  
 "Overview of CompressorAR®," <http://www.compressar.com/products/index.shtml>; Advanced Vascular Dynamics; (Copyright (2002)); (p. 1).  
 Abbott Vascular Devices—ProStar XL 10 [www.perclose.com/products/product.php?id=19](http://www.perclose.com/products/product.php?id=19); last accessed Dec. 5, 2005; (Copyright 1996, 2004); (p. 1).  
 Sigel et al., "The Mechanism of Blood Vessel Closure by High Frequency Electrocoagulation", *Surgery Gynecology & Obstetrics*; (Oct. 1965); vol. 121, No. 4; (pp. 823-831).  
 K.K. Jain, et al., "Repair of small blood vessels with the Neodymium-YAG laser: A preliminary report", *Surgery*, vol. 85, No. 6; (1979) (pp. 684-688).  
 S. Silber, et al., "Vascular Closure Devices for Immediate Sheath Removal after Coronary Interventions: Luxury or Necessity?", ISBN 0-683-30729-0, *Handbook of Coronary Stents*, 3. ed.; (2000); pp. 147-151.  
 International Search Report in co-pending application No. PCT/IL04/00100; Dated: Oct. 15, 2004.  
 Angio-Seal™, 111, 2002, STS Platform Design.  
 European Search Report in co-pending application No. 02703826.4; Dated: Feb. 6, 2009.  
 European Search Report in co-pending application No. 99929684.1; Dated: Apr. 6, 2004.  
 International Search Report in co-pending application No. PCT/IL05/00122; Dated: Dec. 30, 2005.  
 International Search Report in co-pending application No. PCT/IB05/03491; Dated: Feb. 27, 2006.  
 International Search Report in co-pending application No. PCT/IL02/00200; Dated: Jul. 31, 2002.  
 International Search Report in co-pending application No. PCT/IL97/00309; Dated: Feb. 3, 1998.  
 International Search Report in co-pending application No. PCT/IL99/00384; Dated: Nov. 9, 1999.  
 International Search Report in co-pending application No. PCT/US08/73402; Dated: Oct. 22, 2008.  
 International Search Report in co-pending application No. PCT/US08/78826; Dated: Dec. 29, 2008.  
 European Search Report in co-pending application No. EP 08798045.4 issued Jul. 27, 2011.  
 Japanese Office Action in co-pending application No. JP 2007-542157 issued Feb. 1, 2012.  
 Canadian Office Action in co-pending application No. CA 2,514,865 issued Feb. 7, 2012.  
 European Office Action in co-pending application No. EP 05 703 165.0 issued Mar. 29, 2010.  
 European Office Action in co-pending application No. EP 05 703 165.0 issued Dec. 21, 2009.  
 European Office Action in co-pending application No. EP 04 707 612.0 issued Sep. 7, 2011.  
 Korean Notice of Grounds for Refusal in co-pending application No. 10-2003-7012034 issued Dec. 14, 2007.  
 Korean Notice of Grounds for Refusal in co-pending application No. 10-2003-7012034 issued Jun. 16, 2008.  
 Korean Notice of Grounds for Refusal in co-pending application No. 10-2003-7012034 issued Feb. 24, 2009.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/791,448, dated Feb. 7, 2012, 12 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/543,654, dated Aug. 26, 2009, 11 pages.

In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/543,654, dated Jul. 7, 2010, 10 pages.  
 In the U.S. Patent and Trademark Office, Examiner's Interview Summary in re: U.S. Appl. No. 10/543,654, dated Aug. 10, 2010, 3 pages.  
 In the U.S. Patent and Trademark Office, Restriction Requirement in re: U.S. Appl. No. 10/543,654, dated Jan. 22, 2009, 6 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/543,654, dated Oct. 26, 2009, 12 pages.  
 In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/543,654, dated Jul. 7, 2010, 11 pages.  
 In the U.S. Patent and Trademark Office, Examiner Interview Summary in re: U.S. Appl. No. 09/114,817, dated Oct. 20, 1999, 1 page.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 09/114,817, dated Aug. 24, 1999, 5 pages.  
 In the U.S. Patent and Trademark Office, Examiner's Interview Summary in re: U.S. Appl. No. 10/288,843, dated Mar. 1, 2005, 1 page.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/288,843, dated Jan. 11, 2005, 4 pages.  
 In the U.S. Patent and Trademark Office, Notice of Allowance in re: U.S. Appl. No. 09/808,630, dated Oct. 6, 2003, 9 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 09/808,630, dated Sep. 17, 2003, 1 page.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 09/808,630, dated Nov. 25, 2002, 5 pages.  
 In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/797,294, dated Jul. 26, 2011, 17 pages.  
 In the U.S. Patent and Trademark Office, Examiner's Interview Summary in re: U.S. Appl. No. 11/797,294, dated Jun. 17, 2010, 4 pages.  
 In the U.S. Patent and Trademark Office, Notice of Allowance in re: U.S. Appl. No. 09/114,817, dated Dec. 16, 1999, 5 pages.  
 In the U.S. Patent and Trademark Office, Restriction Requirement in re: U.S. Appl. No. 09/598,232, dated Jun. 5, 2002, 4 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 09/598,232, dated Jul. 16, 2002, 7 pages.  
 In the U.S. Patent and Trademark Office, Notice of Allowance in re: U.S. Appl. No. 10/288,843, dated Jul. 6, 2005, 6 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 09/808,630, dated Aug. 18, 2003, 5 pages.  
 In the U.S. Patent and Trademark Office, Restriction Requirement in re: U.S. Appl. No. 09/808,630, dated Jun. 26, 2002, 4 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/791,277 dated Apr. 20, 2011, 9 pages.  
 In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/791,277 dated Dec. 6, 2011, 12 pages.  
 In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 08/715,160, dated Jul. 9, 1997, 7 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 08/715,160, dated Feb. 26, 1997, 6 pages.  
 In the U.S. Patent and Trademark Office, Notice of Allowance in re: U.S. Appl. No. 08/715,160, dated Oct. 2, 1997, 7 pages.  
 In the U.S. Patent and Trademark Office, Examiner's Interview Summary in re: U.S. Appl. No. 08/715,160, dated Sep. 29, 1997, 6 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/471,537, dated Sep. 4, 2008, 6 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/797,294, dated Nov. 13, 2008, 12 pages.  
 In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/797,294, dated Jul. 7, 2009, 12 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/797,294, dated Jan. 15, 2010, 12 pages.  
 In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 11/797,294, dated Aug. 24, 2010, 12 pages.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 11/797,294, dated Feb. 25, 2011, 2010, 16 pages.  
 In the U.S. Patent and Trademark Office, Examiner's Interview Summary in re: U.S. Appl. No. 10/358,130, dated Dec. 7, 2005, 1 page.  
 In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 10/616,887, dated Aug. 24, 2005, 7 pages.  
 In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 10/616,887, dated May 22, 2006, 7 pages.  
 In the U.S. Patent and Trademark Office, Notice of Allowance in re: U.S. Appl. No. 10/616,887, dated Jan. 24, 2007, 8 pages.

## US 8,372,072 B2


Page 6


---

In the U.S. Patent and Trademark Office, Examiner's Interview Summary in re: U.S. Appl. No. 10/616,887, dated Jun. 26, 2006, 3 pages.  
In the U.S. Patent and Trademark Office, Examiner's Interview Summary in re: U.S. Appl. No. 10/616,887, dated Mar. 1, 2006, 3 pages.  
In the U.S. Patent and Trademark Office, Restriction Requirement in re: U.S. Appl. No. 10/616,887, dated May 31, 2005, 5 pages.  
In the U.S. Patent and Trademark Office, Restriction Requirement in re: U.S. Appl. No. 12/192,911, dated Sep. 13, 2011, 11 pages.  
In the U.S. Patent and Trademark Office, Restriction Requirement in re: U.S. Appl. No. 12/245,569, dated Apr. 14, 2011, 9 pages.


In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 12/245,569, dated Jul. 14, 2011, 9 pages.  
In the U.S. Patent and Trademark Office, Final Office Action in re: U.S. Appl. No. 12/245,569, dated Nov. 30, 2011, 8 pages.  
In the U.S. Patent and Trademark Office, Non-Final Office Action in re: U.S. Appl. No. 12/192,911, dated Apr. 26, 2012, 28 pages.  
European Search Report in co-pending application No. EP 08836162 issued May 10, 2012.

\* cited by examiner














FIG. 2C









FIG. 2F







FIG. 2H








FIG. 3

1

## METHODS AND APPARATUS FOR HEMOSTASIS FOLLOWING ARTERIAL CATHETERIZATION

### CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 11/797,294, filed May 2, 2007, now abandoned, which is a continuation U.S. application Ser. No. 10/616,887, filed Jul. 10, 2003, now U.S. Pat. No. 7,223,266, which is a continuation-in-part of U.S. application Ser. No. 10/358,130, filed Feb. 4, 2003, now U.S. Pat. No. 7,115,127, the contents of each are incorporated by reference.

### FIELD OF THE INVENTION

The present invention relates to catheterization systems and methodologies generally and more particularly to post-catheterization closure.

### BACKGROUND OF THE INVENTION

Various techniques are known for arterial catheterization. Following arterial catheterization, it is necessary to promote hemostasis quickly and without undue hardship for the patient.

Applicant's U.S. Pat. Nos. 5,728,134 and 6,048,358, and Published PCT Patent Applications WO 98/11830 and WO 00/02488 describe methods and apparatus for hemostasis that greatly simplifies hemostasis and thus greatly reduces patient discomfort following arterial catheterization. These patent documents, the disclosure of which are hereby incorporated by reference, and the prior art referenced therein are considered to represent the state of the art.

### SUMMARY OF THE INVENTION

The present invention seeks to provide improved systems and methodologies for post-catheterization closure.

There is thus provided in accordance with a preferred embodiment of the present invention a method for producing hemostasis of an artery of a patient having a puncture following arterial catheterization including introducing a hemostasis device including at least one electrode into the vicinity of the puncture, supplying an electric current to the at least one electrode, thereby heating a volume of blood in the vicinity of the puncture, causing coagulation of the blood and causing closure of the puncture and subsequently removing the hemostasis device from the patient.

In accordance with another preferred embodiment of the present invention the at least one electrode includes a pair of electrodes.

In accordance with yet another preferred embodiment of the present invention the introducing includes introducing via a catheter introducer. Additionally, the introducing also includes inflating an anchor balloon attached to an end of the hemostasis device. Alternatively or additionally, the introducing also includes inflating a peripheral balloon. In accordance with still another preferred embodiment of the present invention the removing the hemostasis device includes deflating the peripheral balloon.

In accordance with another preferred embodiment of the present invention the introducing also includes positioning the at least one electrode in close proximity to the volume of blood.

2

Preferably, the supplying includes supplying electrical power at RF frequencies. Additionally, the electrical power includes electrical power in the range of 0.1-10 watts at up to 25 volts.

5 In accordance with yet another preferred embodiment of the present invention the supplying also includes adjusting the electric current based on a feedback measurement.

There is also provided in accordance with another preferred embodiment of the present invention a hemostasis device including a main shaft, at least one balloon and at least one electrode, operable to supply an electric current and to thereby heat a volume of blood adjacent to the at least one electrode and to cause coagulation of the blood and closure of the puncture.

15 In accordance with another preferred embodiment of the present invention the at least one balloon includes at least one anchor balloon, disposed at an end of the main shaft and at least one peripheral balloon, disposed at a location along the main shaft exterior to a wall of the main shaft. Preferably, the volume of blood is delimited by the peripheral balloon and a wall of the artery.

In accordance with yet another preferred embodiment of the present invention the hemostasis device also includes an electrical power source and control module. Additionally, the electrical power source and control module includes a power supply, operative to supply power to the at least one electrode, feedback measurement means and a processor.

25 Preferably, the power supply includes an RF power supply which supplies electrical power at RF frequencies within a range of 0.1-10 watts at up to 25 volts.

In accordance with still another preferred embodiment of the present invention the feedback measurement means is operative to measure at least one of electrical current, blood resistance and blood temperature.

35 Additionally, the processor is operative to adjust the power based on an output from the feedback measurement means.

In accordance with yet another preferred embodiment of the present invention the at least one electrode includes a pair of electrodes.

40 There is further provided in accordance with yet another preferred embodiment of the present invention a method for producing hemostasis of an artery of a patient having a puncture following arterial catheterization, including introducing a hemostasis device including at least one electrode into the vicinity of the puncture, positioning the at least one electrode in proximity with the puncture, supplying an electric current to the at least one electrode, thereby heating a volume of blood in the vicinity of the puncture, causing coagulation of the blood and causing closure of the puncture and subsequently removing the hemostasis device from the patient.

50 In accordance with another preferred embodiment of the present invention the positioning includes inflating an anchor balloon attached to an end of the hemostasis device, inflating a peripheral balloon and subsequently deflating the anchor balloon. Preferably, the volume of blood is delimited by the peripheral balloon and a wall of the artery.

In accordance with still another preferred embodiment of the present invention the at least one electrode includes a pair of electrodes.

60 In accordance with yet another preferred embodiment of the present invention the supplying includes supplying electrical power at RF frequencies. Additionally, the electrical power includes electrical power in the range of 0.1-10 watts at up to 25 volts.

65 In accordance with another preferred embodiment of the present invention the supplying also includes adjusting the electric power based on a feedback measurement.

## BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will be understood and appreciated more fully from the following detailed description, taken in conjunction with the drawings in which:

FIG. 1 is a simplified illustration of a hemostasis device constructed and operative in accordance with a preferred embodiment of the present invention;

FIGS. 2A, 2B, 2C, 2D, 2E, 2F, 2G, 2H and 2I are simplified illustrations of the operation of the apparatus of FIG. 1 in a patient treatment context; and

FIG. 3 is a simplified illustration of a hemostasis device constructed and operative in accordance with another preferred embodiment of the present invention.

## DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

Reference is now made to FIG. 1, which is a simplified illustration of a hemostasis device 100 for producing hemostasis following arterial catheterization, in accordance with a preferred embodiment of the present invention. The hemostasis device 100 is suitable for insertion via a conventional catheter introducer (not shown) following completion of catheterization and removal of the catheter from the catheter introducer.

In accordance with a preferred embodiment of the present invention, hemostasis device 100 comprises a main shaft 102, which has an outer wall 104 and preferably includes at least three bores. A first bore, designated generally by reference numeral 110, extends along the main shaft 102 to an anchor balloon inflation location 112. A second bore 120 extends along the shaft 102 to a peripheral balloon inflation location 122. A third bore, designated generally by reference number 130, contains an electrocoagulation heating device 132 connected to an electrical power source and control module 134 by a connector 136.

Disposed at an end of main shaft 102 at anchor balloon inflation location 112 is an anchor balloon 140. Anchor balloon 140 is selectively inflated, as shown in FIG. 2C, via a stopcock 142 and associated conduit 144 in fluid communication with main shaft 102 via a head element 150. Head element 150 is fixed to main shaft 102 at an end thereof opposite the end at which anchor balloon 140 is located. The interior of head element 150 is in fluid communication with first bore 110 in main shaft 102, which in turn is in fluid communication with the interior of the anchor balloon 140 at anchor balloon inflation location 112.

Disposed adjacent the end of second bore 120 in fluid communication with peripheral balloon inflation location 122, exterior of wall 104, is a peripheral balloon 160. Peripheral balloon 160 is selectively inflated, as shown in FIG. 2E, via second bore 120, via a stopcock 162 and associated conduit 164 that communicate with second bore 120 via head element 150.

In accordance with a preferred embodiment of the present invention, electrocoagulation heating device 132 comprises an electrical conductor 170 connected to an electrocoagulation electrode 176 at an extreme end 178 of third bore 130. A pair of electrical cables 180 and 182 extend from electrical power source and control module 134. In the illustrated embodiment, electrical cable 180 serves as a power supply cable and is connected to electrocoagulation heating device 132 by connector 136. Electrical cable 182 serves as a return current cable and is preferably connected to an electrode 184 attached to a body of a patient.

Electrical power source and control module 134 preferably comprises a power supply, preferably an RF power supply source 186, including a feedback measurement circuit 188. The feedback measurement circuit 188 is preferably operative to measure current, blood resistance or blood temperature and thereby determine progress of hemostasis. The electrical power source and control module 134 also preferably includes a microprocessor 190, operative to adjust the power supplied to hemostasis device 100 according to the blood temperature or other feedback measurement received from feedback measurement circuit 188, in order to achieve optimal coagulation of the blood.

In accordance with a preferred embodiment of the present invention an operator actuation switch 192 is connected along electrical cable 180. In accordance with another preferred embodiment, switch 192 may be obviated and electrical cable 180 connected directly to connector 136.

Reference is now made to FIGS. 2A-2I, which illustrate various steps in a preferred mode of operation of the apparatus of FIG. 1.

FIG. 2A illustrates the hemostasis device 100 about to be inserted into an artery 200 via a conventional catheter introducer assembly 202, following completion of a catheterization procedure and withdrawal of a catheter (not shown) from the catheter introducer assembly 202. The catheter introducer assembly 202 conventionally includes a catheter introducer sheath 204.

FIG. 2B shows the hemostasis device 100 inserted into the catheter introducer assembly 202 such that the outer end of the main shaft 102 extends into the artery 200 well beyond the end of catheter introducer sheath 204. As shown with particularity in FIG. 2B, at this stage both anchor balloon 140 and peripheral balloon 160 are deflated.

Reference is now made to FIG. 2C, which shows initial inflation of the anchor balloon 140, preferably by use of a syringe 220 communicating with first bore 110 via the interior of head element 150, stopcock 142 and associated conduit 144. The inflated anchor balloon 140 preferably has a cusp-type configuration as seen with particularity in FIG. 2C.

Following inflation of the anchor balloon 140, the catheter introducer assembly 202 and the hemostasis device 100 are both withdrawn, such that the catheter introducer sheath 204 is removed from artery 200 only when the anchor balloon 140 already engages the interior wall of artery 200 in sealing engagement with the aperture in the artery 200 through which the catheter introducer sheath 204 is drawn and through which the main shaft 102 presently extends. This stage is shown in FIG. 2D.

As seen in FIG. 2E, initial inflation of the peripheral balloon 160 is effected, preferably by use of a syringe 240 communicating with second bore 120 via head element 150, stopcock 162 and associated conduit 164.

Thereafter, as seen in FIG. 2F, the anchor balloon 140 is deflated and the peripheral balloon 160 is more fully inflated, which preferably causes the extreme end of the main shaft 102 to be withdrawn from the artery 200 to a location lying just outside the artery wall. As seen in FIG. 2F, peripheral balloon 160 is preferably designed to allow a limited volume of blood to collect outside of the artery wall after the anchor balloon 140 is deflated. This volume of blood is located in a region, indicated by reference numeral 250, delimited by the engagement of peripheral balloon 160 with the artery wall.

At this stage, electric power is supplied to the electrode 176 to provide heating of the blood in region 250, causing coagulation thereof, as seen in FIG. 2G. In accordance with the illustrated embodiment of FIG. 1 and as shown in FIG. 2G, the electric power is provided by actuation of switch 192. In

5

accordance with another preferred embodiment, switch **192** is obviated, and the electric power is provided by connecting electrical cable **180** (FIG. 1) directly to connector **136**.

Preferably, the amount of electrical power supplied along electrical cable **180** (FIG. 1) from electrical power source and control module **134** to the electrocoagulation electrode **176** is between 0.1-10 watts at up to 25 volts at RF frequencies.

Once acceptable hemostasis has occurred in region **250**, the peripheral balloon **160** is deflated, as shown in FIG. 2H, preferably by operation of syringe **240** communicating with second bore **120** via head element **150**, stopcock **162** and associated conduit **164**.

Thereafter, the hemostasis device **100** is entirely withdrawn from the patient, leaving a region **260** of hemostasis outside of artery **200**, as shown in FIG. 2I.

Reference is now made to FIG. 3, which is a simplified illustration of a hemostasis device constructed and operative in accordance with another preferred embodiment of the present invention. The embodiment of FIG. 3 is similar to that of FIG. 1, except as described hereinbelow. Elements that occur in both embodiments are identified by the same reference numerals.

In the embodiment of FIG. 3, electrocoagulation heating device **132** comprises a pair of separate electrical conductors **300** extending along third bore **130** connecting electrical power source and control module **134** to a pair of electrocoagulation electrodes **302** at end **178** of third bore **130**. Electrical cables **180** and **182** are both connected to electrocoagulation heating device **132** by connector **136**. The illustrated embodiment shows connector **136** directly connected to electrical cables **180** and **182**.

In the embodiment of FIG. 3, the electrodes **302** may be arranged in mutual coaxial arrangement or in mutual side-by-side arrangement or any other suitable arrangement.

It will be appreciated by persons skilled in the art that the present invention is not limited by what has been particularly shown and described hereinabove. Rather the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove and shown in the drawings as well as modifications and further developments thereof which would occur to a person of ordinary skill in the art upon reading the foregoing description and which are not in the prior art.

The invention claimed is:

**1.** A method for producing hemostasis of an artery of a patient having a puncture following arterial catheterization comprising:

introducing a hemostasis device into a vicinity of the puncture, the hemostasis device comprising:

a main shaft;

an expandable member disposed on the main shaft; and at least one electrode coupled to the main shaft;

expanding the expandable member to form a region delimited by engagement of the expandable member against an outside of an artery wall;

allowing a limited volume of blood to collect outside the artery wall and within the region;

supplying an electric current to said at least one electrode, thereby heating the region causing coagulation of the limited volume of blood in the region and causing closure of said puncture; and

subsequently removing said hemostasis device from the patient.

6

**2.** A method according to claim **1** and wherein said at least one electrode comprises a pair of electrodes.

**3.** A method according to claim **1** and wherein said introducing comprises introducing via a catheter introducer.

**4.** A method according to claim **1** and wherein said introducing also comprises inflating an anchor balloon attached to an end of said hemostasis device.

**5.** A method according to claim **4**, further comprising deflating the anchor balloon.

**6.** A method according to claim **1** and wherein said removing of said hemostasis device comprises deflating said expandable member.

**7.** A method according to claim **1** and wherein said introducing also comprises positioning said at least one electrode in close proximity to the region.

**8.** A method according to claim **1** and wherein said supplying comprises supplying electrical power at RF frequencies.

**9.** A method according to claim **8** and wherein said electrical power comprises electrical power in the range of 0.1-10 watts at up to 25 volts.

**10.** A method according to claim **1** and wherein said supplying also comprises adjusting said electric current based on feedback measurement.

**11.** A method for producing hemostasis of an artery of a patient having a puncture following arterial catheterization comprising:

introducing a hemostasis device into a vicinity of the puncture, the hemostasis device comprising:

a main shaft;

an expandable member disposed on the main shaft; and at least one electrode coupled to the main shaft;

positioning said at least one electrode in proximity with said puncture;

expanding the expandable member to form a region delimited by engagement of the expandable member against an outside of an artery wall;

allowing a limited volume of blood to collect outside the artery wall and within the region;

supplying an electric current to said at least one electrode, thereby heating the region, causing coagulation of the limited volume of blood in the region and causing closure of said puncture; and

subsequently removing said hemostasis device from the patient.

**12.** A method according to claim **11** and wherein said positioning comprises:

inflating an anchor balloon attached to an end of said hemostasis device;

and subsequently deflating said anchor balloon.

**13.** A method according to claim **11** and wherein said at least one electrode comprises a pair of electrodes.

**14.** A method according to claim **11** and wherein said supplying comprises supplying electrical power at RF frequencies.

**15.** A method according to claim **14** and wherein said electrical power comprises electrical power in the range of 0.1-10 watts at up to 25 volts.

**16.** A method according to claim **11** and wherein said supplying also comprises adjusting said electric current based on a feedback measurement.

\* \* \* \* \*